R&D Tax Incentive
Ab Initio is registered with the Australian Industry R&D Tax Incentive as a Registered Service Provider (RSP).
Ab Initio’s R&D and manufacturing activities may qualify for the Australian Government, Department of Industry Science and Resources, R&D Tax Incentive scheme. This means that our clients may be eligible for a 43.5 cents in the dollar cash rebate or a 38.5% tax shield on activities undertaken by Ab Initio. Activities may include formulation R&D, feasibility studies, early phase clinical trial manufacture and CMC regulatory enabling studies and clinical trials. The AusIndustry R&D Tax Incentive is a cost effective means of fast tracking innovative products from the bench to first in human studies.
To be eligible for the AusIndustry R&D Tax Incentive a business must:
be developing an innovative pharmaceutical product.
be spending money on Australian R&D in the current or previous financial year.
have an Australian ABN.
have spent at least $20,000 on R&D activities in Australia
*Tax incentive amounts are subject to change. Clients should seek independent financial advice regarding access to the scheme.
